These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18684623)

  • 1. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.
    Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
    Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives.
    Yamamoto T; Niwa S; Tokumasu M; Onishi T; Ohno S; Hagihara M; Koganei H; Fujita S; Takeda T; Saitou Y; Iwayama S; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3639-42. PubMed ID: 22560585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
    Ogihara T; Kano T; Kakinuma C
    Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity.
    Yamamoto T; Niwa S; Iwayama S; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Yamamoto H; Shoji M
    Bioorg Med Chem; 2006 Aug; 14(15):5333-9. PubMed ID: 16616501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors.
    Pajouhesh H; Feng ZP; Ding Y; Zhang L; Pajouhesh H; Morrison JL; Belardetti F; Tringham E; Simonson E; Vanderah TW; Porreca F; Zamponi GW; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1378-83. PubMed ID: 20117000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2004 Jun; 18(3):309-19. PubMed ID: 15147282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,4-Dihydropyridine derivatives as calcium channel modulators: the role of 3-methoxy-flavone moiety.
    Budriesi R; Bisi A; Ioan P; Rampa A; Gobbi S; Belluti F; Piazzi L; Valenti P; Chiarini A
    Bioorg Med Chem; 2005 May; 13(10):3423-30. PubMed ID: 15848754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
    Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
    Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
    Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
    Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of pranidipine on N-type voltage-dependent Ca2+ channels in mice.
    Murakami M; Mori T; Nakagawasai O; Hagiwara K; Sakurada Y; Mobarakeh II; Murata A; Yamadera F; Miyoshi I; Tan-No K; Yanai K; Tadano T; Iijima T
    Neurosci Lett; 2004 Aug; 367(1):118-22. PubMed ID: 15308311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
    Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
    Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
    Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE
    J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction.
    Nagai H; Minatoguchi S; Chen XH; Wang N; Arai M; Uno Y; Lu C; Misao Y; Onogi H; Kobayashi H; Takemura G; Maruyama R; Fujiwara T; Fujiwara H
    Hypertens Res; 2005 Apr; 28(4):361-8. PubMed ID: 16138567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels.
    Yamamoto T; Ohno S; Niwa S; Tokumasu M; Hagihara M; Koganei H; Fujita S; Takeda T; Saitou Y; Iwayama S; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3317-9. PubMed ID: 21514827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between neural networks (NN) and principal component analysis (PCA): structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues).
    Takahata Y; Costa MC; Gaudio AC
    J Chem Inf Comput Sci; 2003; 43(2):540-4. PubMed ID: 12653519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
    Rhim H; Lee YS; Park SJ; Chung BY; Lee JY
    Bioorg Med Chem Lett; 2005 Jan; 15(2):283-6. PubMed ID: 15603940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents.
    Hosseini M; Miri R; Amini M; Mirkhani H; Hemmateenejad B; Ghodsi S; Alipour E; Shafiee A
    Arch Pharm (Weinheim); 2007 Oct; 340(10):549-56. PubMed ID: 17849444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K
    Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method.
    Hemmateenejad B; Miri R; Akhond M; Shamsipur M
    Arch Pharm (Weinheim); 2002 Dec; 335(10):472-80. PubMed ID: 12506395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.